


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+0.65%
+3.77%
+0.43%
+6.81%
0.00%
PCRX
Pacira BioSciences I
$19.16
Strengths

Earnings are forecast to grow

Upgraded on attractively valued
PCRX Price Performance
$26.35 (-27.29%)
$21.66 (-11.54%)
$25.99 (-26.28%)
$26.59 (-27.94%)
PCRX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Has a weak balance sheet
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PCRX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PCRX Street Sentiment is bullish and have positive views on the near-term outlook
PCRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
What is PCRX current stock price?
What are PCRX stock strengths?
What is PCRX Risk Level?
What is PCRX market cap and volume?
What is PCRX current Stock IQ?
Should I buy PCRX stock right now?
Is PCRX a Strong Buy right now?
What does a 'Strong Buy' rating mean for PCRX?
What does a 'Strong Sell' rating mean for PCRX?
What factors influence PCRX's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+0.65%
+3.77%
+0.43%
+6.81%
0.00%
PCRX
Pacira BioSciences I
Current Price
$19.16
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

PCRX Price Performance
$26.35 (-27.29%)
$21.66 (-11.54%)
$25.99 (-26.28%)
$26.59 (-27.94%)
PCRX Analysts Opinion
PCRX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Has a weak balance sheet
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow
![]()
PCRX Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PCRX Street Sentiment is bullish and have positive views on the near-term outlook
PCRX has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
PCRX Stock IQ
PCRX Latest Analysis
PCRX LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific. Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific unlocking royalties and new revenue channels to support international growth.
Wed Jan 14, 2026
Pacira BioSciences Inc. (PCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Wed Jan 14, 2026
Pacira BioSciences Signs Deal With LG Chem To Commercialize EXPAREL In Select Asia-Pacific Markets . (RTTNews) - Pacira BioSciences Inc. (PCRX) Tuesday announced an agreement with LG Chem to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets.
Tue Jan 13, 2026
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates. Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates despite Exparel sales topping forecasts.
Mon Jan 12, 2026
Pacira Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Revenues. -- Record-high EXPAREL sales driven by volume growth of 7 percent marking strongest fourth quarter performance in three years-- BRISBANE Calif. Jan. 08 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences Inc. (Nasdaq: PCRX) the industry leader in its commitment to deliver innovative non-opioid pain therapies to transform the lives of patients today reported preliminary unaudited total revenue of $726.4 million for the year
Thu Jan 8, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
PCRX Stock trends
PCRX Stock performance
PCRX Stock analysis
PCRX investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.